Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1013 in Hemodialysis Subjects with Secondary Hyperparathyroidism
NCT06747247Phase 2Completed
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Apr 2023
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of MT1013 in secondary hyperparathyroidism (SHPT), sponsored by Shaanxi Micot Technology Co., Ltd.. Started Apr 2023; status: completed.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT06747247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747247.